Cargando…

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forlano, Roberta, Sivakumar, Mathuri, Mullish, Benjamin H., Manousou, Pinelopi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368436/ https://www.ncbi.nlm.nih.gov/pubmed/35955434 http://dx.doi.org/10.3390/ijms23158307

Ejemplares similares

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2022)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023)

Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
por: Forlano, Roberta, et al.
Publicado: (2021)

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Jambulingam, Nila, et al.
Publicado: (2023)

Current and future pharmacological therapies for managing cirrhosis and its complications
por: Kockerling, David, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023)

Screening for NAFLD—Current Knowledge and Challenges
por: Forlano, Roberta, et al.
Publicado: (2023)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2020)

THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2014)

Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
por: Zhou, Jin, et al.
Publicado: (2021)

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
por: Maestri, Marta, et al.
Publicado: (2023)

Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis
por: Alisi, Anna, et al.
Publicado: (2012)

Astaxanthin Prevents Alcoholic Fatty Liver Disease by Modulating Mouse Gut Microbiota
por: Liu, Huilin, et al.
Publicado: (2018)

The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms
por: JASIRWAN, Chyntia Olivia Maurine, et al.
Publicado: (2019)

Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota
por: Wang, Tianjiao, et al.
Publicado: (2021)

Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease
por: Zhang, Qi, et al.
Publicado: (2022)

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
por: Forlano, Roberta, et al.
Publicado: (2020)

Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids
por: Sun, QinMei, et al.
Publicado: (2022)

Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
por: Xie, Chencheng, et al.
Publicado: (2019)

Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents
por: Tokuhara, Daisuke
Publicado: (2021)

Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
por: Airola, Carlo, et al.
Publicado: (2023)

Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions
por: Vajro, Pietro, et al.
Publicado: (2012)

Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
por: Borrelli, Antonella, et al.
Publicado: (2018)

Effects of Tea against Alcoholic Fatty Liver Disease by Modulating Gut Microbiota in Chronic Alcohol-Exposed Mice
por: Li, Bangyan, et al.
Publicado: (2021)

Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Ji, Yun, et al.
Publicado: (2019)

Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis
por: Quesada-Vázquez, Sergio, et al.
Publicado: (2020)

Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients
por: Tsai, Hui-Ju, et al.
Publicado: (2021)

Dysbiosis of gut microbiota after cholecystectomy is associated with non‐alcoholic fatty liver disease in mice
por: Wang, Qihan, et al.
Publicado: (2021)

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
por: Ni, Yiming, et al.
Publicado: (2022)

Alcohol-dependent downregulation of apolipoprotein H exacerbates fatty liver and gut microbiota dysbiosis in mice
por: Liu, Yaming, et al.
Publicado: (2022)

The effects of dietary supplementation with inulin and inulin‐propionate ester on hepatic steatosis in adults with non‐alcoholic fatty liver disease
por: Chambers, Edward S., et al.
Publicado: (2018)

Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver
por: Gupta, Haripriya, et al.
Publicado: (2021)

Roles of Gut Microbiota in Alcoholic Liver Disease
por: Zhang, Daya, et al.
Publicado: (2023)

Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota
por: Du, Fan, et al.
Publicado: (2021)

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
por: Chen, Hui-Ting, et al.
Publicado: (2020)

Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
por: Gupta, Haripriya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b34o7mi8cai6ceivbvq5o91f7m